TCRX
Tscan Therapeutics Inc

848
Mkt Cap
$63.56M
Volume
716,500.00
52W High
$2.57
52W Low
$0.8824
PE Ratio
-1.12
TCRX Fundamentals
Price
$1.12
Prev Close
$1.13
Open
$1.14
50D MA
$1.06
Beta
1.22
Avg. Volume
461,574.98
EPS (Annual)
-$0.9999
P/B
0.52
Rev/Employee
$72,711.27
$71.51
Loading...
Loading...
News
all
press releases
HC Wainwright Issues Positive Outlook for TCRX Earnings
TScan Therapeutics, Inc. (NASDAQ:TCRX - Free Report) - HC Wainwright raised their Q1 2026 earnings estimates for TScan Therapeutics in a research note issued on Wednesday, March 4th. HC Wainwright...
MarketBeat·3d ago
News Placeholder
More News
News Placeholder
FY2030 Earnings Estimate for TCRX Issued By HC Wainwright
TScan Therapeutics, Inc. (NASDAQ:TCRX - Free Report) - Equities research analysts at HC Wainwright issued their FY2030 EPS estimates for shares of TScan Therapeutics in a note issued to investors on...
MarketBeat·4d ago
News Placeholder
TScan Therapeutics (NASDAQ:TCRX) Price Target Raised to $5.00
Wedbush lifted their price target on TScan Therapeutics from $4.00 to $5.00 and gave the stock an "outperform" rating in a research note on Thursday...
MarketBeat·4d ago
News Placeholder
TScan Therapeutics (NASDAQ:TCRX) Releases Quarterly Earnings Results, Beats Estimates By $0.09 EPS
TScan Therapeutics (NASDAQ:TCRX - Get Free Report) announced its quarterly earnings data on Wednesday. The company reported ($0.18) earnings per share for the quarter, beating the consensus estimate...
MarketBeat·5d ago
News Placeholder
TScan Therapeutics, Inc. (TCRX) Reports Q4 Loss, Misses Revenue Estimates
TScan Therapeutics (TCRX) delivered earnings and revenue surprises of +34.31% and -37.08%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·5d ago
News Placeholder
Earnings Breakdown: TScan Therapeutics Q4
read more...
Benzinga·5d ago
News Placeholder
Recursion Pharmaceuticals (RXRX) Reports Q4 Loss, Beats Revenue Estimates
Recursion Pharmaceuticals (RXRX) delivered earnings and revenue surprises of +24.11% and +39.36%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·12d ago
News Placeholder
TScan Therapeutics (TCRX) Projected to Post Quarterly Earnings on Wednesday
TScan Therapeutics (NASDAQ:TCRX) will be releasing its Q4 2025 earnings before the market opens on Wednesday, March 4. (View Earnings Report at...
MarketBeat·12d ago
News Placeholder
TScan Therapeutics (NASDAQ:TCRX) Trading Up 4.6% - Here's What Happened
TScan Therapeutics (NASDAQ:TCRX) Shares Up 4.6% - Here's Why...
MarketBeat·18d ago
News Placeholder
TScan Therapeutics, Inc. (NASDAQ:TCRX) Receives Consensus Recommendation of "Hold" from Brokerages
TScan Therapeutics, Inc. (NASDAQ:TCRX - Get Free Report) has received an average rating of "Hold" from the seven ratings firms that are currently covering the firm, MarketBeat Ratings reports. One...
MarketBeat·18d ago
<
1
2
...
>

Latest TCRX News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.